Estimated read time: 3-4 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK]
[IN] PHA
[SU] SVY TRI NPT
TO MEDICAL, NATIONAL, AND SCIENCE EDITORS:
Cyclenium Pharma and Southern Research Institute Announce Drug
Discovery and Development Collaboration
SHERBROOKE, Quebec and BIRMINGHAM, Ala., April 17, 2014
/PRNewswire-USNewswire/ -- Cyclenium Pharma Inc., an emerging
pharmaceutical company specializing in the research and development of
novel drug candidates based on proprietary macrocyclic chemistry,
today announced the signing of a discovery and co-development
agreement with Southern Research Institute, a not-for-profit 501(c)(3)
scientific research organization founded in 1941. The collaboration
will utilize Cyclenium's proprietary libraries of next generation
macrocyclic molecules and associated hit-to-lead optimization
expertise in combination with Southern Research's extensive
capabilities in target screening, compound profiling and preclinical
development. The goal is to discover and jointly develop new clinical
candidates for the treatment of cancer, infectious diseases and
neurological conditions.
"We are very pleased to have initiated this collaboration with a
prestigious organization like Southern Research," stated Helmut
Thomas, Ph.D., President & CEO of Cyclenium. "Their breadth of
expertise and long history of successful contributions to drug
discovery and development will provide strong synergy for our
proprietary macrocyclic technology with the expectation of multiple
novel candidates resulting from our joint efforts over the next few
years."
"Cyclenium's proprietary macrocyclic libraries are well suited for use
against many of the challenging targets we are currently working on,"
stated Mark J. Suto, Ph.D. Vice-President Drug Discovery Division
Southern Research Institute. "For example, screening of currently
available small molecule libraries has not been very successful in the
identification of new antibiotics and in targets associated with
disrupting protein-protein interactions. The Cyclenium macrocycle
libraries are unique in that they combine the complexities found in
natural products with the drug-like properties needed for successful
drug discovery. We are looking forward to collaborating with Cyclenium
in the identification of new therapeutics."
About Cyclenium Pharma Cyclenium Pharma is an emerging pharmaceutical
research and development company pursuing development of selected
product opportunities in areas of unsatisfied medical need, while
simultaneously creating a second generation macrocyclic drug discovery
technology. Cyclenium is building value through progression of
internal programs and establishing collaborations with innovative
pharmaceutical and biotechnology companies seeking to modulate
difficult disease targets. For more on Cyclenium Pharma, please see:
www.cyclenium.com.
About Southern Research Institute Southern Research Institute is a
not-for-profit 501(c)(3) scientific research organization founded in
1941 that conducts preclinical drug discovery and development,
advanced engineering research in materials, systems development, and
environment and energy research. Approximately 500 scientific and
engineering team members support clients and partners in the
pharmaceutical, biotechnology, defense, aerospace, environmental and
energy industries. From discovery to clinical trials, Southern
Research contributes to the search for new and better drugs and
vaccines through a comprehensive continuum of capabilities. As a
contract research organization, Southern Research provides preclinical
drug development and clinical trial support services to pharmaceutical
and biotechnology companies on an outsourced basis. Southern Research
is headquartered in Birmingham, AL, with additional laboratories and
offices in Wilsonville and Huntsville, AL, Frederick, MD, Durham, NC,
Houston, TX, and Cartersville, GA. For more information visit:
http://www.southernresearch.org.
Contacts: Helmut Thomas, Ph.D. President & CEO Cyclenium Pharma Inc.
Telephone: + 1 514-745-1439 hthomas@cyclenium.com
Mark J. Suto, Ph.D Vice President Drug Discovery Division Southern
Research Institute Telephone: +1 205-581-2522
suto@southernresearch.org
SOURCE Southern Research Institute
-0- 04/17/2014
/Web Site: http://www.southernresearch.org
CO: Southern Research Institute
ST: Quebec Alabama
IN: PHA
SU: SVY TRI NPT
PRN
-- DC07985 --
0000 04/17/2014 18:00:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
